ES2242287T3 - Microparticulas para la administracion controlada de moleculas biologicamente activas. - Google Patents
Microparticulas para la administracion controlada de moleculas biologicamente activas.Info
- Publication number
- ES2242287T3 ES2242287T3 ES98932506T ES98932506T ES2242287T3 ES 2242287 T3 ES2242287 T3 ES 2242287T3 ES 98932506 T ES98932506 T ES 98932506T ES 98932506 T ES98932506 T ES 98932506T ES 2242287 T3 ES2242287 T3 ES 2242287T3
- Authority
- ES
- Spain
- Prior art keywords
- chemically homogeneous
- synthetic
- microparticle according
- homogeneous microparticle
- natural
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000011859 microparticle Substances 0.000 title claims abstract description 62
- 229920001059 synthetic polymer Polymers 0.000 claims abstract description 6
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 56
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 54
- 239000000243 solution Substances 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- 229920001577 copolymer Polymers 0.000 claims description 14
- 229930182830 galactose Natural products 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 10
- -1 oxyethylene glycols Chemical class 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- 150000001720 carbohydrates Chemical group 0.000 claims description 9
- 230000003993 interaction Effects 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 210000003494 hepatocyte Anatomy 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- 229930186217 Glycolipid Natural products 0.000 claims description 6
- 108090000288 Glycoproteins Proteins 0.000 claims description 6
- 102000003886 Glycoproteins Human genes 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 102000009027 Albumins Human genes 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 5
- 108010002913 Asialoglycoproteins Proteins 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 5
- 102000014150 Interferons Human genes 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 5
- 238000013019 agitation Methods 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 239000003114 blood coagulation factor Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 150000002482 oligosaccharides Chemical class 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 108010084541 asialoorosomucoid Proteins 0.000 claims description 3
- 238000000975 co-precipitation Methods 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 229920000447 polyanionic polymer Polymers 0.000 claims description 3
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- 239000012460 protein solution Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000001690 Factor VIII Human genes 0.000 claims description 2
- 108010054218 Factor VIII Proteins 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 102000008072 Lymphokines Human genes 0.000 claims description 2
- 108010074338 Lymphokines Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 108010058846 Ovalbumin Proteins 0.000 claims description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 2
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000007900 aqueous suspension Substances 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 229940097362 cyclodextrins Drugs 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 229960000301 factor viii Drugs 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 150000002270 gangliosides Chemical class 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 229960001438 immunostimulant agent Drugs 0.000 claims description 2
- 239000003022 immunostimulating agent Substances 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 2
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- 229940092253 ovalbumin Drugs 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000000941 radioactive substance Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 235000004252 protein component Nutrition 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000004005 microsphere Substances 0.000 description 47
- 239000006185 dispersion Substances 0.000 description 23
- 101000987090 Homo sapiens MORF4 family-associated protein 1 Proteins 0.000 description 20
- 102100027862 MORF4 family-associated protein 1 Human genes 0.000 description 20
- 238000003760 magnetic stirring Methods 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 108010017507 Ricinus communis agglutinin-1 Proteins 0.000 description 13
- 150000008064 anhydrides Chemical class 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- XKQWKOLYUBPIAK-PLNGDYQASA-N (Z)-2-(2-methoxyethyl)but-2-enedioic acid Chemical compound COCC/C(/C(=O)O)=C/C(=O)O XKQWKOLYUBPIAK-PLNGDYQASA-N 0.000 description 11
- 230000004520 agglutination Effects 0.000 description 11
- 239000012154 double-distilled water Substances 0.000 description 11
- 239000008055 phosphate buffer solution Substances 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 238000002296 dynamic light scattering Methods 0.000 description 8
- 238000004141 dimensional analysis Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 235000004443 Ricinus communis Nutrition 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 101710186708 Agglutinin Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 239000001116 FEMA 4028 Substances 0.000 description 3
- 101710146024 Horcolin Proteins 0.000 description 3
- 101710189395 Lectin Proteins 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 101710179758 Mannose-specific lectin Proteins 0.000 description 3
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 3
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 3
- 240000000528 Ricinus communis Species 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 239000000910 agglutinin Substances 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101000941284 Homo sapiens Gastric triacylglycerol lipase Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229920005603 alternating copolymer Polymers 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000002338 glycosides Chemical group 0.000 description 2
- 102000014957 human gastric lipase Human genes 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 101000635854 Homo sapiens Myoglobin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 108010042430 galactose receptor Proteins 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003571 opsonizing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- ZDWVWKDAWBGPDN-UHFFFAOYSA-O propidium Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 ZDWVWKDAWBGPDN-UHFFFAOYSA-O 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97RM000418A IT1293088B1 (it) | 1997-07-10 | 1997-07-10 | Microparticelle per il rilascio controllato di molecole biologicamente attive e loro uso in terapia, profilassi e diagnostica in vitro e in |
| ITRM970418 | 1997-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2242287T3 true ES2242287T3 (es) | 2005-11-01 |
Family
ID=11405168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98932506T Expired - Lifetime ES2242287T3 (es) | 1997-07-10 | 1998-07-09 | Microparticulas para la administracion controlada de moleculas biologicamente activas. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1003482B1 (en]) |
| AT (1) | ATE293958T1 (en]) |
| AU (1) | AU8240998A (en]) |
| DE (1) | DE69829975T2 (en]) |
| ES (1) | ES2242287T3 (en]) |
| IT (1) | IT1293088B1 (en]) |
| WO (1) | WO1999002135A1 (en]) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| US6932861B2 (en) | 2000-11-28 | 2005-08-23 | Fmc Corporation | Edible PGA coating composition |
| ES2324525T3 (es) | 2001-06-20 | 2009-08-10 | Dainippon Sumitomo Pharma Co., Ltd. | Metodo para promover transferencia de acidos nucleicos. |
| JP2008067717A (ja) * | 2001-06-20 | 2008-03-27 | Dainippon Sumitomo Pharma Co Ltd | 核酸導入を促進させる方法 |
| US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| CA2510199A1 (en) | 2002-12-17 | 2004-07-08 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity |
| US7229966B2 (en) | 2002-12-17 | 2007-06-12 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| US7186692B2 (en) | 2002-12-17 | 2007-03-06 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| CA3004363A1 (en) | 2015-11-06 | 2017-05-11 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Composition comprising a biocompatible and biodegradable polymer, nanocarries and a drug and methods of making and using the same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2660556B1 (fr) * | 1990-04-06 | 1994-09-16 | Rhone Poulenc Sante | Microspheres, leur procede de preparation et leur utilisation. |
| IT1244511B (it) * | 1991-04-15 | 1994-07-15 | Isi Ist Sierovaccinogeno Ital | Idrogeli a base di policarbossilati sintetici e proteine per il rilascio controllato di farmaci e procedimento per la loro preparazione. |
| PT644771E (pt) * | 1992-06-11 | 2002-12-31 | Alkermes Inc | Sistema de entrega da droga eritropoietina |
| NZ265818A (en) * | 1993-04-19 | 1997-09-22 | Medisorb Technologies Internat | Compositions of nucleic acids encapsulated with molecules that facilitate uptake and integration into living cells |
-
1997
- 1997-07-10 IT IT97RM000418A patent/IT1293088B1/it active IP Right Grant
-
1998
- 1998-07-09 ES ES98932506T patent/ES2242287T3/es not_active Expired - Lifetime
- 1998-07-09 AT AT98932506T patent/ATE293958T1/de not_active IP Right Cessation
- 1998-07-09 EP EP98932506A patent/EP1003482B1/en not_active Expired - Lifetime
- 1998-07-09 AU AU82409/98A patent/AU8240998A/en not_active Abandoned
- 1998-07-09 DE DE69829975T patent/DE69829975T2/de not_active Expired - Lifetime
- 1998-07-09 WO PCT/IT1998/000192 patent/WO1999002135A1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IT1293088B1 (it) | 1999-02-11 |
| DE69829975D1 (de) | 2005-06-02 |
| ATE293958T1 (de) | 2005-05-15 |
| ITRM970418A0 (en]) | 1997-07-10 |
| AU8240998A (en) | 1999-02-08 |
| EP1003482B1 (en) | 2005-04-27 |
| DE69829975T2 (de) | 2006-03-09 |
| WO1999002135A1 (en) | 1999-01-21 |
| EP1003482A1 (en) | 2000-05-31 |
| ITRM970418A1 (it) | 1999-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2286040T3 (es) | Microesferas de liberacion prolongada. | |
| EP1060741B1 (en) | Sustained release microspheres | |
| US6090925A (en) | Macromolecular microparticles and methods of production and use | |
| US5981719A (en) | Macromolecular microparticles and methods of production and use | |
| Guo et al. | Delivery strategies for macromolecular drugs in cancer therapy | |
| Jeon et al. | Affinity-based growth factor delivery using biodegradable, photocrosslinked heparin-alginate hydrogels | |
| ES2706000T3 (es) | Procedimiento de producción de sistemas de administración utilizando composiciones poliméricas biodegradables preformadas | |
| US20050008572A1 (en) | Nanoparticular tumor targeting and therapy | |
| US5654006A (en) | Condensed-phase microparticle composition and method | |
| US20100081202A1 (en) | Process for facilitating nucleic acid transfer | |
| ES2242287T3 (es) | Microparticulas para la administracion controlada de moleculas biologicamente activas. | |
| Crooke et al. | Lung tissue delivery of virus-like particles mediated by macrolide antibiotics | |
| EP0684812B1 (en) | Condensed-phase microparticle composition and method | |
| US20110136727A1 (en) | Compositions and methods for rapid selection of pathogen binding agents | |
| EP1369110A1 (en) | Production of nanoparticles from methyl vinyl ether copolymer and maleic anhydride for the administration of hydrophilic pharmaceuticals, more particularly of puric and pyrimidinic bases | |
| CN111298116B (zh) | 多肽载药温敏脂质体及其制备方法和应用 | |
| Zhang et al. | Novel peptide-directed liposomes for targeted combination therapy of breast tumors | |
| US20050013791A1 (en) | Cytokine-inducing material and cytokine-inducing instrument | |
| Gill | Resealed erythrocytes as a potential drug carrier system | |
| ES2816632B2 (es) | Hidrogeles cargados con nanoparticulas de silice mesoporosa (nms) funcionalizadas con polietilenglicol (peg) para la liberacion controlada de farmacos | |
| KR102510170B1 (ko) | 활성산소종 감응성을 가지는, 고분자가 코팅된 금 나노입자-압타머 나노구조체의 개발 및 응용 | |
| US9125949B2 (en) | Direct utilization of plasma proteins for the in vivo assembly of protein-drug/imaging agent conjugates, nanocarriers and coatings for biomaterials | |
| WO2007127813A2 (en) | Modulation of signal transduction by site specific ultrasound agent delivery of transmembrane acting compounds | |
| Shilpi et al. | Resealed Erythrocytes: A Biological Carrier for Drug Delivery | |
| AU4758300A (en) | Novel liposomal vector complexes and their use in gene therapy |